anti-TCRVbeta Chimeric Antigen Receptors (CARs)

Proposed use

For use in immunotherapy, for treating or preventing cancer, autoimmune disease or any disease characterized by the presence of pathogenic T cells.

Problem addressed

Current CAR-based immunotherapies eliminate either the whole or 50% of healthy T cells, thus rendering patients profoundly immunosuppressed. Our anti-TCRVbeta Chimeric Antigen Receptor immunotherapy would leave >90% of the T cell immunity intact, thus reducing considerably the probability of life-threatening infections.

Technology overview

Within a healthy T cell population, each cell expresses 1 of 22 different types of TCRVbeta chains. Pathological T cells express the same TCRVbeta which is only expressed in <10% of normal T cells.

We have developed anti-TCRVbeta Chimeric Antigen Receptors which can target pathological T cells in a highly selective manner, leaving >90% of the patient’s T cells and T cell-dependent immunity intact.

Benefits

• Targets and selectively kills pathogenic T cells, e.g. T cell lymphomas and autoimmune diseases
• Leaves >90% of healthy T cells intact
• Leaves T cell dependent immunity intact
• Reduces probability of life-threatening infections

Intellectual property information

A PCT application was filled in August 2023. The priority date is August 2022.